Catalog No. | BS1301 |
---|---|
Product Name | PSCA (V71) polyclonal antibody |
Applications | WB |
Alternative Name | PSCA; PRO232; Prostate stem cell antigen; UNQ206 |
Swiss-Prot | O43653 |
Host | Rabbit |
Reactivity | Human,Mouse,Rat |
Application_all | WB: 1:500~1:1000 |
Product | Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
Purification&Purity | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE). |
Storage&Stability | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. |
Specificity | PSCA (V71) polyclonal antibody detects endogenous levels of Prostate Stem Cell Antigen protein. |
BiowMW | ~ 18 kDa |
Note | For research use only, not for use in diagnostic procedure. |
Immunogen | Synthetic peptide, corresponding to amino acids 41-90 of Human PSCA. |
Background
Prostate stem cell antigen (PSCA) is a 123 amino acid glycosylated protein that shares homology with the Thy-1/Ly-6 family of glycosyl-phosphatidylinositol GPI)-anchored cell surface antigens. The PSCA gene maps to chromosome 8q24.2 and transcripts are most prevalent in prostate and placenta. The gene encoding c-myc is also located on chromosome 8q and like PSCA, is overexpressed in a large number of prostate cancers. Transcripts for PSCA are also abundant in urothelial tumors, and levels of PSCA transcripts increase in confluent RT112 bladder carcinomas, suggesting that PSCA is a marker for urothelial and gastric tissue carcinogenesis. Among prostate cancer cell surface antigens, PSCA is expressed in over 80% of prostate carcinomas and correlates well to certain prostate cancer phenotypes such as prostate cancer bone metastates.